The transcription and processing of pre-mRNA in eukaryotic cells are regulated in part by reversible phosphorylation of the C-terminal domain of the largest RNA polymerase II subunit. The CTD phosphatase, FCP1, catalyzes the dephosphorylation of RNAP II and is thought to play a major role in polymerase recycling. This study describes a family of small CTD phosphatases (SCP) that preferentially catalyze the dephosphorylation of Ser 5 within the consensus repeat. The preferred substrate for SCP1 is RNAP II phosphorylated by TFIIH. Like FCP1, the activity of SCP1 is enhanced by the RAP74 subunit of TFIIF. Expression of SCP1
INTRODUCTION
The largest subunit of RNA polymerase (RNAP) II contains a C-terminal domain (CTD) comprised of multiple repeats of the consensus sequence Tyr 1 Ser 2 Pro 3 Thr 4 Ser 5 Pro 6 Ser 7 . The progression of RNAP II through the transcription cycle is regulated by both the state of CTD phosphorylation and the specific site of phosphorylation within the consensus repeat (1, 2) . The emerging overview of this process is that unphosphorylated RNAP II, designated RNAP IIA, enters the preinitiation complex where phosphorylation of Ser 5 is catalyzed by TFIIH (which contains cdk7/cyclin H subunits) concomitant with transcript initiation (3, 4) . This generates the phosphorylated form of RNAP II, designated RNAP IIO. Ser 5 phosphorylation facilitates the recruitment of the 7-methyl G capping enzyme complex (5) (6) (7) (8) (9) . Phosphorylation of Ser 2 is catalyzed by the cyclin-dependent kinase P-TEFb (which contains cdk9/cyclin T subunits) (10, 11) . Although Ser 5 phosphorylation precedes Ser 2 phosphorylation (12), it is not clear if the dephosphorylation of Ser 5 precedes Ser 2 phosphorylation. During transcript elongation in yeast there is extensive turnover of Ser 2 phosphates mediated by FCP1 and Ctk1, the putative P-TEFb homolog (13) . Finally, dephosphorylation of Ser 2 by the FCP1 phosphatase regenerates RNAP IIA thereby completing the cycle (14) .
FCP1 is a class C (PPM) phosphatase containing a BRCT domain that is required for interaction with RNAP II and dephosphorylation of the CTD (15, 16) . FCP1 interacts with and is stimulated by RAP74, the larger subunit of TFIIF (16, 17) . Class C phosphatases are resistant to inhibitors that block other classes of Ser/Thr phosphatases and bind Mg 2+ or Mn 2+ in the binuclear metal center of the catalytic site (18, 19) . The ψ((DXDX(T/V)ψ( motif (where ψ= hydrophobic residue) present in the FCP1 homology domain characterizes a subfamily of class C phosphatases with both Asp residues being essential for activity (20, 21) .
Synthetic lethality is observed between mutant FCP1 and reduced levels of RNAP II in S. cerevisiae and S. pombe, indicating that FCP1 is an essential gene (21, 22) . It remains uncertain whether the activity of yeast FCP1 accounts for the dephosphorylation in vivo of both Ser 5 and Ser 2 and whether this is the sole activity that catalyzes CTD dephosphorylation. Mutations in FCP1 lead to increased phosphorylation of Ser 2 suggesting that it functions in vivo in the dephosphorylation of Ser 2 (13) . Yeast FCP1 appears more specific for Ser 2 phosphate when synthetic peptides are used as substrate (23) . However, mammalian FCP1 dephosphorylates both Ser 2 and Ser 5 in vitro in the context of native RNAP II (24) . Furthermore, modifications such as that catalyzed by the Ess1/Pin1 peptidyl prolyl isomerase may alter the activity and specificity of FCP1 (25) (26) (27) . Given the importance of CTD phosphorylation in gene expression (28) , it is essential to know if additional CTD phosphatases exist and if so, their specificity and the mechanisms by which they are targeted to RNAP II at discrete stages of the transcription cycle.
Although FCP1 is the only reported CTD phosphatase, examination of the databases reveals additional genes that consist principally of a domain with homology to the CTD phosphatase domain of FCP1. Three closely related human genes encoding small proteins with CTD phosphatase domain homology, but lacking a BRCT domain, have been identified. In the present study we show that a gene located on chromosome 2 encodes a nuclear CTD phosphatase. This protein preferentially dephosphorylates Ser 5 within the CTD of RNAP II and is stimulated by RAP74. Expression of this small CTD phosphatase (SCP1) inhibits activated transcription from a variety of promoter-reporter gene constructs whereas expression of a mutant lacking phosphatase activity enhances transcription. This newly identified small CTD phosphatase appears to play an important role in the regulation of RNAP II transcription.
EXPERIMENTAL PROCEDURES
Materials-SCP1 and SCP2 were obtained as EST clones from Invitrogen. The full-length cDNA for SCP1 (261 aa, AL520011), the cDNA encoding the variant of SCP1 (214 aa, BE300370) and SCP2 (AL520463) were subcloned into EcoR1-Xho1 sites of pGEX4T-1 and pcDNA3Flag vectors by PCR. All clones were sequenced and the corrected sequences have been deposited in the NCBI data base 1 . The D96E, D98N mutant of SCP1 261 and the corresponding mutant of SCP1 214, D48E and D50N, were generated by QuikChange (Stratagene). All constructs were verified by sequencing. GST fusions were purified by glutathione-sepharose chromatography and SCP1 261 was generated by cleavage at the thrombin site encoded in the vector. Recombinant FCP1 was expressed and purified as described previously (24) . Human recombinant casein kinase II (CKII) and mouse recombinant MAPK2/ERK2 were obtained from Upstate Biotechnology. Human CTDK1/CTDK2 were purified as described by Payne and Dahmus (29) . Human TFIIH was generously provided by Jean-Marc Egly (30) . Human P-TEFb was partially purified from HeLa S-100 extract by chromatography on Heparin-Sepharose (Amersham Biosciences), DEAE 15HR (Millipore) HiTrap S and Phenyl-Superose (both from Amersham Biosciences). P-TEFb was dialyzed against 25 mM Hepes, pH 7.9, 20% glycerol, 25 mM KCl, 0.1 mM EDTA, 1 mM DTT, 1 mM PMSF. Human recombinant Cdc2 kinase was purchased from New England Biolabs. Rabbits were immunized with GST-SCP1 214. Anti-GST antibodies were adsorbed to GST agarose and rabbit anti-SCP1 IgG (Antibody 6703) was prepared by ammonium sulfate fractionation and protein G-sepharose chromatography. RNAP II antibodies (8WG16, H5 and H14) were obtained from Covance.
Preparation and Purification of 32 P-RNAP IIO Isozymes and 32 P-GST-CTDo-Calf thymus
RNAP IIA was purified by the method of Hodo and Blatti (31) with modifications as described by Kang and Dahmus (32) . Specific isozymes of 32 P-labeled RNAP IIO were prepared by phosphorylation at the most C-terminal serine (CKII site) in the largest subunit of purified RNAP IIA with recombinant CKII and [γ-32 P]ATP (17, 33) , followed by CTD phosphorylation in the presence of 2 mM ATP with either purified CTDK1/CTDK2, TFIIH, P-TEFb, recombinant MAPK2/ERK2 or recombinant Cdc2 kinase. The RNAP IIO isozymes were individually purified over a DE53 column with a step elution of 500 mM KCl (29) . Because only the most C-terminal serine is labeled with 32 P and lies outside the consensus repeat, dephosphorylation by CTD phosphatase results in an electrophoretic mobility shift in SDS-PAGE of subunit IIo to the position of subunit IIa without the loss of label. GST-CTD was prepared and purified as previously described (34) . 32 P-labeled GST-CTDo was subsequently prepared from GST-CTDa by CKII followed by MAPK2/ERK2. GST-CTDo was purified over a glutathione-agarose column with a step elution of 15 mM glutathione. CTD phosphatase assays utilizing RNAP IIO and GST-CTDo as substrate were performed as described previously (35) Immunofluorescence-Cells grown on coverslip were fixed in 2% paraformaldehyde, neutralized and blocked using 2.5% FCS/PBS. Rabbit polyclonal IgG 6703 was used at 1:100 dilution, followed by goat anti-rabbit IgG H+L chains conjugated to Alexa Fluor 488 (1:250) (Molecular Probes). Mouse anti EEA1 was used at 1:1000 followed by goat anti-mouse IgG conjugated to Alexa Fluor 594 (1:250). Omission of primary antibodies was used as negative control. The coverslips were viewed using the Zeiss Axiophot which is equipped with a Hamamatsu Orca ER firewire camera that runs on Improvision Openlab 3.0.9 software.
Immunoprecipitations-For immunoprecipitation experiments, 75% confluent COS7 cells from a 10 cm dish were harvested in lysis buffer (PBS containing 1% NP40, 1 mM DTT and protease inhibitors). Lysates were incubated with 20 µl sepharose-conjugated anti-SCP1 (6703) IgG at 4 o C for 6 hr. Beads were washed with PBS and the complexes were evaluated by western blotting using specific anti-RNAP II antibodies. Rabbit anti-SNX1 antibody was used as control IgG.
RESULTS

SCP1 is an RNAP II CTD phosphatase
The alignment of three human proteins that are closely related to one another and have homology to the phosphatase domain of human FCP1 is shown in Figure 1A . All contain the signature motif Ψ((DXDX(T/V)Ψ(. SCP1, located on chromosome 2q35, was initially designated nuclear LIM interacting factor (NLI-IF) in the genome entry (36) . The full-length 261 aa protein is encoded by 7 exons; a shorter NH 2 terminal splice version of 214 aa is present in EST databases. SCP1 has ~20% homology to human FCP1 in the phosphatase domain while the 3 SCP proteins are >90% homologous in this region. SCP2/OS4 located on chromosome 12q13 was co-amplified with CDK4 in sarcomas (37) and SCP3/HYA22 located on chromosome 3q22 was part of a large chromosome deletion in a lung carcinoma cell line (38) . To determine whether SCP1 has phosphatase activity, the protein was expressed as a GST-fusion and both SCP1 261 and SCP1 214 were assayed using PNθP as substrate. As reported for FCP1 from S. pombe (23) utilizing PNθP as substrate, the pH optimum for SCP1 phosphatase activity is near 5 ( Figure 2A ). Phosphatase activity was Mg 2+ -dependent and resistant to the phosphatase inhibitors okadaic acid and microcystin ( Figure 2B ). Ca 2+ could not substitute for Mg 2+ . Mutations of Asp96 to Glu (D96E) had little to no effect on phosphatase activity (data not shown) whereas mutating Asp98 to Asn (D98N) in conjunction with the D96E mutation completely abolished phosphatase activity ( Figure 2B ). SCP1 is thus a class 2C phosphatase whose activity is dependent on acidic residues in the conserved DXD motif. SCP2 exhibited similar phosphatase activity ( Figure 2B ).
To determine whether GST-SCP1 214 has CTD phosphatase activity, GST-CTDo and RNAP IIO were utilized as substrates and the activity of SCP1 was compared directly with that of FCP1. Recombinant CTDo (rCTDo) and RNAP IIO utilized as substrate in these experiments were prepared by the phosphorylation of purified GST-CTDa or RNAP IIA with casein kinase II (CKII) in the presence of [γ-32 P]ATP followed by phosphorylation with MAPK2/ERK2 in the presence of excess unlabeled ATP. MAPK2/ERK2 was used in these initial experiments because it phosphorylates both GST-CTDa and RNAP IIA with comparable efficiency (24) . As expected, FCP1 efficiently converts RNAP IIO to RNAP IIA in a processive manner ( Figure 2C , lanes 7-12) (24, 35) . Even high concentrations of FCP1 did not result in measurable dephosphorylation of rCTDo ( Figure 2C , lanes 1-6) consistent with the idea that a docking site on RNAP II is required for activity (17) . GST-SCP1 214 catalyzed the dephosphorylation of both RNAP IIO and GST-CTDo with comparable efficiency ( Figure 2D ). In contrast to FCP1, the SCP1 catalyzed dephosphorylation of RNAP IIO appears non-processive in that a number of phosphorylated intermediates are visible in SDS-PAGE. SCP1 is specific for dephosphorylation of the consensus repeat in that the phosphate at the CKII site is not removed. As shown below, the pattern of dephosphorylation varies depending on the CTD kinase used in the preparation of RNAP IIO. Mutant SCP1 (D96E, D98N) lacked activity on either substrate (data not shown).
SCP1 is thus a CTD phosphatase that acts on both RNAP IIO and rCTDo. SCP2 exhibits comparable CTD phosphatase activity when RNAP IIO is utilized as substrate (see Figure 4 ).
SCP1 preferentially dephosphorylates Ser 5 of the CTD heptad repeat
To determine the specificity of SCP1 with respect to its ability to dephosphorylate specific positions within the consensus repeat, RNAP IIO isozymes were prepared in vitro by the phosphorylation of RNAP IIA with CTD kinases of known specificity. TFIIH, P-TEFb and MAPK2/ERK2 preferentially phosphorylate Ser 5 when synthetic peptides serve as substrate (39, 40) whereas Cdc2 kinase phosphorylates Ser 2 and Ser 5 (41) . Although the specificity appears relaxed when RNAP II serves as substrate, RNAP IIO prepared with Cdc2 kinase is clearly distinct from RNAP IIO generated by other CTD kinases (24) . Results presented in Figure 3A indicate that RNAP IIO, prepared by the phosphorylation of RNAP IIA with distinct CTD kinases, exhibit a differential sensitivity to dephosphorylation with SCP1. SCP1 most efficiently dephosphorylates RNAP IIO generated by TFIIH and was unable to dephosphorylate RNAP IIO prepared with Cdc2 kinase. SCP1 was also unable to dephosphorylate RNAP IIO generated by Abl tyrosine kinase (data not shown). The dephosphorylation of RNAP IIO isozymes prepared with P-TEFb, MAPK2/ERK2 and CTDK1/CTDK2 occurred at a reduced rate relative to that of RNAP IIO prepared with TFIIH. Furthermore, while the dephosphorylation reaction appears processive for RNAP IIO prepared by TFIIH, it is clearly non-processive for RNAP IIO generated by MAPK2/ERK2. In contrast FCP1 shows no preference for RNAP IIO generated by TFIIH and efficiently dephosphorylates RNAP IIO generated by Cdc2 kinase (24) . These results suggest SCP1 differs from FCP1 in substrate specificity, showing relative preference for the dephosphorylation of Ser 5 in the heptad repeat.
To investigate the relative reactivity of SCP1 for Ser 2 and Ser 5, a synthetic 28 aa peptide containing 4 heptad repeats phosphorylated exclusively on Ser 2 or on Ser 5 was dephosphorylated in the presence of increasing amounts of SCP1. As shown in Figure 3B , SCP1 preferentially dephosphorylates the Ser 5 phosphopeptide compared to the Ser 2 phosphopeptide.
This substrate specificity contrasts to that reported for FCP1 from S. pombe which preferentially dephosphorylate the Ser 2 phosphopeptide (23). Mammalian FCP1, within a comparable concentration range, did not act on either phosphopeptide (data not shown). These results using synthetic phosphopeptide substrates confirm that SCP1 preferentially dephosphorylates Ser 5 phosphate of the CTD.
Effect of RAP74 on the activity of SCP1
The RAP74 subunit of TFIIF stimulates CTD phosphatase activity of FCP1 (17) .
Furthermore, the domains of FCP1 that bind RAP74 are required for FCP1-dependent viability in S. cerevisiae (15) . Therefore, it was of interest to determine if RAP74 can also influence the activity of SCP. CTD phosphatase activity was measured at low enzyme concentrations to more readily detect stimulatory effects of RAP74. As shown in Figure 4 , RAP74 shifted the dose response curve for SCP1 catalyzed dephosphorylation of RNAP IIO to an approximately 10-fold lower concentration. The CTD phosphatase activity of the GST-fusion forms of SCP1 261, SCP1 214 and SCP2 were also enhanced by RAP74. The presence of comparable concentrations of BSA does not stimulate the CTD phosphatase activity of SCP1. In support of the conclusion that RAP74 stimulates the activity of SCPs, RAP74 bound directly to GST-SCP1 but not to GST (data not shown). The binding and stimulatory effects of RAP74 suggest that TFIIF is important for optimal CTD phosphatase activity for both FCP1 and SCP1.
SCP1 is located in the nucleus associated with RNAP II
Although SCP1 lacks an obvious nuclear localization sequence, it is found in the nucleus.
Immunofluorescence microscopy using a rabbit polyclonal anti-SCP1 antibody demonstrated nuclear localization of endogenous SCP1 in COS7 cells (Figure 5 B) . Co-staining with DAPI for nuclear identification and with the early endosomal marker EEA1 for cellular detail confirmed the specific localization of SCP1 in nuclei ( Figure 5 panels A and B) .
Co-immunoprecipitation was used to assess the association of SCP1 with RNAP II.
Sepharose-immobilized anti-SCP1 IgG 6703 was used to immunoisolate SCP1 from COS7 cells. Immunoisolates were resolved by SDS-PAGE and blotted with anti-RNAP II antibodies.
As shown in Figure 5C , RNAP II was present in SCP1 immunoprecipitates indicating that SCP1
and RNAP II either interact directly or are in the same macromolecular complex. To determine whether SCP1 preferentially associated with either Ser 2 or Ser 5 phosphorylated RNAP IIO, lysates were prepared in the presence of EDTA, to inhibit phosphatase activity. SCP1
immunoprecipitates were then blotted with monoclonal antibodies specific for Ser 2 phosphate (H5) and Ser 5 phosphate (H14). Both forms of RNAP IIO were present in COS7 cell lysates.
Ser 5 phosphate-enriched RNAP IIO appeared to be preferentially associated with SCP1 in immunoprecipitates as indicated by the ratios of co-immunoprecipitated RNAP IIO relative to the amount of RNAP IIO contained in the extract ( Figure 5C ).
SCP1 affects RNAP II transcription in vivo
To assess the effect of SCP1 on transcription in vivo, the activity of a variety of luciferase reporter gene constructs was examined in the presence or absence of cotransfected SCP1.
Targeting a Gal 4-DNA binding domain SCP1 fusion or the phosphatase-inactive Gal 4-SCP1 mutant upstream of a thymidine kinase promoter-luciferase reporter (Gal 4-TK-Luc) had no significant effect on transcriptional activity ( Figure 6A ). Interestingly, untethered SCP1 in the presence of several reporter constructs had no significant effect on reporter gene expression whereas the inactive mutant resulted in a significant stimulation of expression from the E1A-Luc, pGL3-Luc and Gal4-TATA-Luc constructs ( Figure 6B ). The phosphatase-minus SCP1 mutant increased luciferase activity 1.5-to 6-fold. (24) . The relative specificity of FCP1 also differs from SCP1 in that unlike FCP1, SCP1 shows preference for the dephosphorylation of TFIIH phosphorylated RNAP IIO. Figure 2C and D that, when RNAP IIO phosphorylated with MAPK2/ERK2 is utilized as substrate, the specific activity of SCP1 is substantially lower than that of FCP1. This difference in specific activity is in part due to the fact that MAPK2/ERK2 phosphorylated RNAP IIO is an especially poor substrate for SCP1 (Figure 3 ) whereas FCP1 dephosphorylates different isozymes of RNAP IIO with comparable efficiency (24) . The amount of SCP1 required to dephosphorylate MAPK2/ERK2 phosphorylated RNAP IIO is 50 to 100 fold higher than that required to dephosphorylate TFIIH phosphorylated RNAP IIO. Furthermore, the BRCT domain and the C-terminus of FCP1 that may facilitate its interaction with RNAP II (16) are absent from SCP1. Most importantly, without a better understanding of the factors that influence the recruitment of SCP1 to complexes containing RNAP IIO, it is difficult to interpret differences in specific activity in a binary reaction. The finding that SCP1 dephosphorylates rCTDo and RNAP IIO with comparable efficiency whereas FCP1 does not dephosphorylate rCTDo even at concentrations 100 times higher than that required to dephosphorylate RNAP IIO, suggest that the interaction of SCP1 and FCP1 with the CTD require different molecular interactions.
It is clear from the results presented in
During the transcription cycle, protein complexes assemble and disassemble on the CTD in a dynamic and regulated manner. Ser 5 phosphorylation is detected primarily at the promoter region, whereas Ser 2 phosphorylation is seen in coding regions (12) 
